

This claim listing will replace all prior versions and listings of claims in the application:

Claim Listing:

- 1.-25. (Cancelled)
26. (Currently amended) A method for generating an immune response in a patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula C*pG, wherein the immunostimulatory oligonucleotide compound is at least 6 nucleotides in length, wherein C* is a non-natural pyrimidine nucleoside selected from the group consisting of 5-hydroxycytosine, 5-hydroxymethylcytosine, N4-alkylcytosine and 4-thiouracil, and G is guanosine and p is an internucleotide linkage selected from the group consisting of phosphorothiate and phosphorodithioate.
27. (Canceled) The method according to claim 26, wherein the oligonucleotide analog immunostimulatory compound is administered in combination with an antibiotic, antigen, allergen, vaccine, antibody, cytotoxic agent, antisense oligonucleotide, gene therapy vector, DNA vaccine, adjuvant, or combination thereof.
28. (Original) The method according to claim 26, wherein the immunostimulatory oligonucleotide compound is conjugated to an antigen or vaccine.
29. (Original) The method according to claim 28, wherein such conjugation is to the 3'-end of the oligonucleotide compound.
- 30-33. (Canceled)
34. (Currently amended) A method for treating a cancer patient, such method comprising administering to the patient an immunostimulatory oligonucleotide compound, comprising an immunostimulatory dinucleotide of formula C*pG, wherein the immunostimulatory oligonucleotide compound is at least 6 nucleotides in length, wherein C* is a non-natural pyrimidine nucleoside selected from the group consisting of 5-hydroxycytosine, 5-hydroxymethylcytosine, N4-alkylcytosine and 4-thiouracil, and G is guanosine and p is an internucleotide linkage selected from the group consisting of phosphorothiate and phosphorodithioate.

35. (Original) The method according to claim 34, wherein the immunostimulatory oligonucleotide compound is administered in combination with a chemotherapeutic compound.
- 36-38. (Canceled)
- 39.-70. (Canceled)
71. (Currently amended) The method according to claim 26, wherein the immunostimulatory oligonucleotide ~~analog-immunostimulatory~~ compound is administered in combination with an antibiotic, antigen, allergen, vaccine, antibody, cytotoxic agent, antisense oligonucleotide, gene therapy vector, DNA vaccine, adjuvant, or combination thereof.
72. (Currently amended) The method according to claim 34, wherein the immunostimulatory oligonucleotide ~~analog-immunostimulatory~~ compound is administered in combination with an antibiotic, antigen, allergen, vaccine, antibody, cytotoxic agent, antisense oligonucleotide, gene therapy vector, DNA vaccine, adjuvant, or combination thereof.